We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 434

RK health insights 19 November 2015
  • Russell Kennedy
  • Australia
  • November 19 2015

The Federal Government is set to remove 17 common over-the-counter medicines (including paracetamol and aspirin) from the Pharmaceutical Benefits

Regulating the nip and tuck: cosmetic medical services growth expands
  • Maddocks
  • Australia
  • May 21 2015

Cosmetic medicine is one of Australia's fastest growing consumer markets, yet the AUD $1 billion1 consumer market is largely unregulated. On the

Harper Review dispenses important recommendations for the life sciences sector
  • DLA Piper LLP
  • Australia
  • May 6 2015

The long-awaited Harper Review final report was released on 31 March 2015. This update highlights key recommendations relevant to the life sciences

Food law: quick bites and upcoming calendar
  • King & Wood Mallesons
  • Australia
  • April 30 2015

The ACCC is seeking leave to appeal the Federal Court decision dismissing its case against Pfizer for alleged misuse of market power and exclusive

Traversing the patent cliff
  • DLA Piper LLP
  • Australia
  • April 29 2015

On 25 February 2015, the Federal Court handed down its much-anticipated judgment in the matter of ACCC v Pfizer Australia Pty Ltd. In dismissing the

Harper Review - implications for the private health insurance industry
  • DLA Piper LLP
  • Australia
  • April 10 2015

On 31 March 2015 the final report of the Competition Policy Review Panel chaired by Professor Ian Harper (Harper Review) was released. The Harper

ACCC takes action against health service providers
  • Lander & Rogers
  • Australia
  • April 10 2015

While claims for damages in tort and contract are common sources of liability for health service providers, recent actions by the Australian

Australian Federal Court decides protecting your brand against generic pharmaceuticals is not a misuse of market power
  • Bird & Bird
  • Australia
  • March 18 2015

In a decision which will be welcomed by many pharmaceutical companies the Federal Court of Australia recently dismissed proceedings instituted by the

Substantial market power now you have it, now you don’t. The decision in ACCC v Pfizer
  • Johnson Winter & Slattery
  • Australia
  • March 17 2015

The recent Federal Court decision in ACCC v Pfizer serves as strong reminder that market power is not static but must be assessed in the context of a

ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk
  • Herbert Smith Freehills LLP
  • Australia
  • March 3 2015

The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had misused